New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
09:09 EDTINSY, FLXN, MNKBMO Capital specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Maris, along with President & CEO Nathaniel Katz, MD of Analgesic Solutions, discuss whether the FDA is looking for alternatives to complement the opioid pain relief medications on the market, including Mallinckrodt’s Xartemis and MNK-155, Flexion’s FX005 and Insys’s Subsys on an Analyst/Industry conference call to be held on May 23 at 10 am.
News For MNK;FLXN;INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 28, 2014
06:47 EDTINSYInsys paid doctors with troubled pasts to market drug, NY Times reports
Five of the 20 physicians who received the most money from Insys Therapeutics to promote its painkiller drug Subsys recently faced legal or disciplinary action, New York Times reports, citing an analysis of the federal Open Payments database. Reference Link
November 25, 2014
06:29 EDTMNKMallinckrodt says Questcor received subpoena from FTC in June
Mallinckrodt (MNK) disclosed in its quarterly regulatory filing that on June 11, Questcor received a subpoena and Civil Investigative Demand from the Federal Trade Commission seeking documentary materials and information regarding the FTC’s investigation into whether Questcor’s acquisition of certain rights to develop, market, manufacture, distribute, sell and commercialize Synacthen Depot from Novartis (NVS) violates the antitrust laws.
November 24, 2014
07:04 EDTINSYInsys Therapeutics receives FDA orphan drug designation to CBD candidate
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its pharmaceutical cannabidiol, or CBD, candidate for the treatment of pediatric schizophrenia. This marks the fifth ODD for the company's CBD program.
November 20, 2014
09:26 EDTFLXNFlexion management to meet with Summer Street
Subscribe for More Information
November 19, 2014
12:04 EDTINSYInsys Therapeutics cannabidiol receives FDA orphan designation
Subscribe for More Information
09:16 EDTMNKOn The Fly: Pre-market Movers
Subscribe for More Information
07:01 EDTMNKMallinckrodt reports Q4 adjusted EPS $1.68, consensus $1.41
Reports Q4 revenue $789.3M, consensus $757.86M.
November 18, 2014
15:21 EDTMNKNotable companies reporting before tomorrow's open
Subscribe for More Information
November 14, 2014
17:27 EDTMNKPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
09:51 EDTMNKMallinckrodt management to meet with Oppenheimer
Meeting to be held in Europe on November 20 hosted by Oppenheimer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use